| Literature DB >> 35767653 |
James D Byrne1,2,3,4,5,6,7, David Gallo8, Hannah Boyce1, Sarah L Becker1, Kristi M Kezar9, Alicia T Cotoia9, Vivian R Feig1, Aaron Lopes1,2,3, Eva Csizmadia8, Maria Serena Longhi10, Jung Seung Lee1,2,3,11, Hyunjoon Kim1,2,3, Adam J Wentworth1,2,3, Sidharth Shankar8, Ghee Rye Lee8, Jianling Bi5, Emily Witt5, Keiko Ishida1,2,3, Alison Hayward3,12, Johannes L P Kuosmanen2,3, Josh Jenkins2,3, Jacob Wainer1,2,3, Aya Aragon2, Kaitlyn Wong1, Christoph Steiger1,2,3, William R Jeck13, Dustin E Bosch14, Mitchell C Coleman7, Douglas R Spitz7, Michael Tift9, Robert Langer2,3, Leo E Otterbein8, Giovanni Traverso1,2,3.
Abstract
Carbon monoxide (CO) has long been considered a toxic gas but is now a recognized bioactive gasotransmitter with potent immunomodulatory effects. Although inhaled CO is currently under investigation for use in patients with lung disease, this mode of administration can present clinical challenges. The capacity to deliver CO directly and safely to the gastrointestinal (GI) tract could transform the management of diseases affecting the GI mucosa such as inflammatory bowel disease or radiation injury. To address this unmet need, inspired by molecular gastronomy techniques, we have developed a family of gas-entrapping materials (GEMs) for delivery of CO to the GI tract. We show highly tunable and potent delivery of CO, achieving clinically relevant CO concentrations in vivo in rodent and swine models. To support the potential range of applications of foam GEMs, we evaluated the system in three distinct disease models. We show that a GEM containing CO dose-dependently reduced acetaminophen-induced hepatocellular injury, dampened colitis-associated inflammation and oxidative tissue injury, and mitigated radiation-induced gut epithelial damage in rodents. Collectively, foam GEMs have potential paradigm-shifting implications for the safe therapeutic use of CO across a range of indications.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35767653 PMCID: PMC9576196 DOI: 10.1126/scitranslmed.abl4135
Source DB: PubMed Journal: Sci Transl Med ISSN: 1946-6234 Impact factor: 19.319